Market Overview

Merck Says FDA Acknowledged Resubmission of NDA for Ezetimibe, Atorvastatin Tablets

Related MRK
KEYTRUDA® (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
Agilent Company Dako, Announces FDA Approval of New Companion Diagnostic for Lung Cancer
Bristol-Myers drug approved (Investor's Business Daily)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin tablets, an investigational combination medicine. The updated NDA was deemed complete for review after Merck submitted additional data in response to the FDA's Complete Response Letter issued last year. Merck expects the FDA's review to be completed in the first half of 2013.

Merck is continuing to move forward with planned filings for the ezetimibe and atorvastatin combination tablet in additional countries around the world.

Posted-In: News FDA


Related Articles (MRK)

Get Benzinga's Newsletters